(Rockville, MD, November 10, 2020) – Fina Biosolutions LLC (“FinaBio”) is pleased to announce that it has received a Certificate of Patent entitled “Expression and Purification of CRM Proteins and Related Proteins, and Protein Domains” from the European Patent Office(EPO). EP Patent No. 3099800 is directed to the expression and purification of the conjugate vaccine protein CRM197 in E.coli.
“Our goal is to lower the vaccine cost barrier and grant people in need access to life-saving vaccines,” said Dr. Andrew Lees, Founder, and CEO of FinaBio. “We are pleased to announce that we succeeded in creating a needed vaccine protein, CRM197, efficiently, and cost-effectively. FinaBio’s proprietary production method will facilitate the availability of vaccines to protect adults and children in developing countries from pneumonia, meningitis, and more.”